Current development of adeno-associated viral vectors

Drug News and Perspectives

Volumn 18, Issue 5, 2005, Pages 311-316

  Romano, Gaetano ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; BLOOD CLOTTING FACTOR 9; IMMUNOSUPPRESSIVE AGENT; PARVOVIRUS VECTOR; TACROLIMUS; VIRUS VECTOR;

CANAVAN DISEASE; CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE COURSE; GENE TRANSFER; HEMOPHILIA B; HUMAN; MUTAGENESIS; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM; PHASE 1 CLINICAL TRIAL; REVIEW;

ADENOVIRIDAE; ANIMALS; CANAVAN DISEASE; CLINICAL TRIALS; CYSTIC FIBROSIS; DEPENDOVIRUS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MUTATION; PARKINSON DISEASE;

EID: 27144509758     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2005.18.5.917326     Document Type: Review

References (75)

1. Romano, G., Micheli, P., Pacilio, C. and Giordano, A. Latest developments in gene transfer technology: Achievements, perspectives, and controversies over therapeutic applications. Stem Cells 2000, 18: 19-39.
2. Romano, G., Pacilio, C. and Giordano, A. Gene transfer technology in therapy: Current applications and future goals. Stem Cells 1999, 17: 191-202.
3. Romano, G. Gene transfer in experimental medicine. Drug News Perspect 2003, 16: 267-76.
4. Romano, G. Current development of lentiviral-mediated gene transfer. Drugs News Perspect 2005, 18: 128-34.
5. Janson, C., McPhee, S., Bilaniuk, L. et al. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 2002, 13: 1391-412.
6. Lawlor, P.A. and During, M.J. Gene therapy for Parkinson's disease. Expert Rev Mol Med 2004, 2004: 1-18.
7. Anderson, W.F. Excitement in gene therapy. Hum Gene Ther 2001, 12: 1483-4.
8. Flotte, T.R., Zeitlin, P.L., Reynolds, T.C. et al. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: A two-part clinical study. Hum Gene Ther 2003, 14: 1079-88.
9. Wagner, J.A., Nepomuceno, I.B., Messner, A.H. et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther 2002, 13: 1349-59.
10. Aitken, M.L., Moss, R.B., Waltz, D.A. et al. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther 2001, 12: 1907-16.
11. Kay, M.A., Manno, C.S., Ragni, M.V. et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000, 24: 257-61.
12. Manno, C.S., Chew, A.J., Hutchinson, S. et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003, 101: 2963-72.
13. Flotte, T.R., Brantly, M.L., Spencer, L.T. et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther 2004, 15: 93-128.
14. Blacklow, N.R., Hoggan, M.D., Kapikian, A.Z. et al. Epidemiology of adenovirus-associated virus infection in a nursery population. Am J Epidemiol 1968, 88: 368-78.
15. Schlehofer, J.R., Ehrbar, M., zur Hausen, H. Vaccinia virus, herpes simplex virus, and carcinogens induce DNA amplification in a human cell line and support replication of a helper-virus dependent parvovirus. Virology 1986, 152: 110-7.
16. Berns, K.I., Pinkerton, T.C., Thomas, G.F. et al. Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells. Virology 1975, 68: 556-60.
17. Podsakoff, G., Wong, K.K., Jr. and Chatterjee, S. Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol 1994, 68: 5656-66.
18. Russell, D.W., Miller, A.D. and Alexander, I.E. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc Natl Acad Sci USA 1994, 91: 8915-9.
19. Flotte, T.R. Gene therapy progress and prospects: Recombinant adeno-associated virus (rAAV) vectors. Gene Ther 2004, 11: 805-10.
20. Gao, G., Alvira, M.R., Somanathan, S. et al. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci USA 2003, 100: 6081-6.
21. Chiorini, J.A., Kim, F., Yang, L. and Kotin, R.M. Cloning and characterization of adeno-associated virus type 5. J Virol 1999, 73: 1309-19.
22. Chiorini, J.A., Yang, L., Liu, Y. et al. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J Virol 1997, 71: 6823-33.
23. Rutledge, E.A., Halbert, C.L. and Russell, D.W. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol 1998, 72: 309-19.
24. Xiao, W., Chirmule, N., Berta, S.C. et al. Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999, 73: 3994-4003.
25. Summerford, C. and Samulski, R.J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998, 72: 1438-45.
26. Summerford, C., Bartlett, J.S., Samulski, R.J. AlphaVbeta5 integrin: A co-receptor for adeno-associated virus type 2 infection. Nat Med 1999, 5: 78-82.
27. Qing, K., Mah, C., Hansen, J. et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 1999, 5: 71-7.
28. Kaludov, N., Brown, K.E., Walters, R.W. et al. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 2001, 75: 6884-93.
29. Zabner, J., Seiler, M., Walters, R. et al. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000, 74: 3852-8.
30. Kotin, R.M. and Berns, K.I. Organization of adeno-associated virus DNA in latently infected Detroit 6 cells. Virology 1989, 170: 460-7.
31. Kotin, R.M., Siniscalsco, M., Samulski, R.J. et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990, 87: 2211-5.
32. Kotin, R.M., Linden, R.M. and Berns, K.I. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 1992, 11: 5071-8.
33. Kotin R.M., Menninger, J.C., Ward, D.C. et al. Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics 1991, 10: 831-4.
34. Samulski, R.J., Zhu, X., Xiao, X. et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991, 10: 3941-50.
35. Xie, Q., Bu, W., Bhatia, S. et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci USA 2002, 99: 10405-10.
36. Seisenberger, G., Ried, M.U., Endress, T. et al. Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science 2001, 294: 1929-32.
37. Bartlett, J.S., Wilcher, R. and Samulski, R.J. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol 2000, 74: 2777-85.
38. Damke, H., Baba, T., Warnock, D.E. et al. Induction of mutant dynamin specifically blocks endocytic coated vesicle formation. J Cell Biol 1994, 127: 915-34.
39. Hinshaw, J.E. and Schmid, S.L. Dynamin self-assembles into rings suggesting a mechanism for coated vesicle budding. Nature 1995, 374: 190-2.
40. Takey, K., McPherson, P.S., Schmid, S.L. and Camilli, P.D. Tubular membrane invaginations coated by dynamin rings are induced by GTP-gammaS in nerve terminals. Nature 1995, 374: 186-90.
41. Hansen, J., Qing, K., Kwon, H.J. et al. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J Virol 2000, 74: 992-6.
42. Srivastava, A. Obstacles to human hematopoietic stem cell transduction by recombinant adeno-associated virus 2 vectors. J Cell Biochem Suppl 2002, 38: 39-45.
43. Duan, D., Yue, Y., Yan, Z. et al. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 2000, 105: 1573-87.
44. Yan, Z., Zak, R., Gant Luxon, G.W. et al. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol 2002, 76: 2043-53.
45. Qing, K., Hansen, J., Weigel-Kelley, K.A. et al. Adeno-associated virus type 2-mediated gene transfer: Role of cellular FKBP52 protein in transgene expression. J Virol 2001, 75: 8968-76.
46. Richardson, W.D. and Westphal, H. A cascade of adenovirus early functions is required for expression of adeno-associated virus. Cell 1981, 27: 133-41.
47. Grimm, D., Kay, M.A. and Kleinschmidt, J.A. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 2003, 7: 839-50.
48. Matsushita, T., Okada, T., Inaba, T. et al. The adenovirus E1A and E1B19K genes provide a helper function for transfection-based adeno-associated virus production. J Gen Virol 2004, 85: 2209-14.
49. Blouin, V., Brument, N., Toublanc, E. et al. Improving rAAV production and purification: Towards the definition of a scaleable process. J Gene Med 2004, 6: S223-8.
50. Smith, R.H., Ding, C. and Kotin, R.M. Serum-free production and column purification of adeno-associated virus type 5. J Virol Methods 2003, 114: 115-24.
51. Summerford, C. and Samulski, R.J. Viral receptors and vector purification: New approaches for generating clinical-grade reagents. Nat Med 1999, 5: 587-8.
52. Rabinowitz, J.E., Rolling, F., Li, C. et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002, 76: 791-801.
53. Rabinowitz, J.E., Boules, D.E., Faust, S.M. et al. Cross-dressing the virion: The transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J Virol 2004, 78: 4421-32.
54. Davidson, B.L., Stein, C.S., Heth, J.A. et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA 2000, 97: 3428-32.
55. Buning, H., Ried, M.U., Perabo, L. et al. Receptor targeting of adeno-associated virus vectors. Gene Ther 2003, 10: 1142-51.
56. Loiler, S.A., Conlon, T.J., Song, S. et al. Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver. Gene Ther 2003, 10: 1551-8.
57. Wu, P., Xiao, W., Conlon, T. et al. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 2000, 74: 8635-47.
58. Peden, C.S., Burger, C., Muzyczka, N. and Mandel, R.J. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 2004, 78: 6344-59.
59. Blacklow, N.R., Hoggan, M.D., Sereno, M.S. et al. A seroepidemiologic study of adenovirus-associated virus infection in infants and children. Am J Epidemiol 1971, 94: 359-66.
60. Chirmule, N., Propert, K., Magosin, S. et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999, 6: 1574-83.
61. Erles, K., Sebokova, P. and Schlehofer, J.R. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 1999, 59: 406-11.
62. Georg-Fries, B., Biederlack, S., Wolf, J. and zur Hausen, H. Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology 1984, 134: 64-71.
63. McCarty, D.M., Monahan, P.E. and Samulski, R.J. Self-inactivating recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001, 8: 1248-54.
64. Harper, S.Q., Hauser, M.A., Dellorusso, C. et al. Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy. Nat Med 2002, 8: 253-61.
65. Duan, D., Yue, Y., Yan, Z. et al. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat Med 2000, 6: 595-8.
66. Nakai, H., Storm, T.A. and Kay, M.A. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol 2000, 18: 527-32.
67. Sun, L., Li, J. and Xiao, X. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med 2000, 6: 599-602.
68. Check, E. Second cancer case halts gene-therapy trials. Nature 2003, 421: 305.
69. McCormack, M.P. and Rabbitts, T.H. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2004, 350: 913-22.
70. Weitzman, M.D., Kyostio, S.R., Kotin, R.M. et al. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci USA 1994, 91: 5808-12.
71. Donsante, A., Vogler, C., Muzyczka, N. et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther 2001, 8: 1343-6.
72. Miller, D.G., Rutledge, E.A. and Russell, D.W. Chromosomal effects of adeno-associated virus vector integration. Nat Genet 2002, 30: 147-8.
73. Nakai, H., Montini, E., Fuess, S. et al. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet 2003, 34: 297-302.
74. Lazzareschi, D., Mincione, G., Coppa, A. et al. Oncogenes and antioncogenes involved in human thyroid carcinogenesis. J Exp Clin Canc Res 1997, 16: 325-32.
75. Gan, D.D., Macaluso, M., Cinti, C. et al. How does a normal cell become a cancer cell? J Exp Clin Cane Res 2003, 22: 509-16.